Abstract
Inflammation and oxidative stress contribute to the progression of nonalcoholic steatohepatitis (NASH)...
Highlights
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disorder in developed countries
Hepatic fibrosis and activated hepatic stellate cells (Ac-HSCs) are attenuated by Angiotensin-II type 1 Receptor Blocker (ARB), and L-carnitine is effective for nonalcoholic steatohepatitis (NASH) by ameliorating oxidative stress, but neither agent is effective in a clinical setting
The combination treatment with L-carnitine and Angiotensin-II type Receptor Blocker (ARB) resulted in a synergistic antifibrotic effect greater than that resulting from either drug alone
Summary
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disorder in developed countries. L-Carnitine (4-N-trimethylammonium-3-hydroxybutyric acid), which is involved in β-oxidation of fatty acids, is a nutrient conditionally synthesized from methionine and lysine in the brain, liver, and kidneys, especially, the liver is the main tissue for carnitine synthesis [6], and is mainly obtained from meat and dairy products [7]. It is an accepted treatment for mitochondrial myopathy and encephalomyopathy as well as other states of primary and. We examined the effect of the combination of L-carnitine and ARB on NASH fibrosis using a rat model fed a Choline-Deficient/L-Amino Acid-defined (CDAA) diet
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
